Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Turn Therapeutics Inc.NASDAQ: TTRX
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings of -$23.36M in Q1 FY2026
Q1 FY2026 retained earnings was -$23.36M.
Context
- Retained earnings amounted to 125.3% of total assets at the end of Q1 FY2026.
- Retained earnings grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (22.39M) USD
- Year-over-year change
- -16.6%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.39M) | -16.6% |
| FY2024 | 2024-12-31 | (19.2M) | -10.1% |
| FY2023 | 2023-12-31 | (17.43M) | — |
Retained Earnings vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 retained earnings of -$23.36M is the highest of the 9 companies compared; the peer median is -$228.67M.
- Retained earnings amounts to 125.3% of total assets for TTRX, versus a peer median of 531.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
TTRXTurn Therapeutics Inc. | Mar 2026 | -$23.36M | — | — | 125.3% |
| Mar 2026 | -$92.79M | -33.7% | — | 883.3% | |
| Mar 2026 | -$148.72M | -26.3% | — | 500.7% | |
| Mar 2026 | -$159.06M | -47.1% | — | 91.8% | |
| Mar 2026 | -$203.22M | -10.7% | — | 562.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$254.12M | -72.6% | — | 380.5% |
| Apr 2026 | -$256.76M | -4.1% | — | 1727.3% | |
| Mar 2026 | -$482.81M | -17.1% | — | 177.4% | |
| Mar 2026 | -$2.14B | +2.9% | — | 1149.6% | |
| Peer median (excluding TTRX) | -$228.67M | -21.7% | — | 531.5% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.